AstraZeneca: Small Cell Lung Carcinoma trials

The registry lists 25 Small Cell Lung Carcinoma studies with AstraZeneca as lead sponsor. 3 are open to participants now and 8 have results posted.

Phase 1 10Phase 2 4Phase 3 6No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous DurvalumabRecruitingNCT07391670Phase 1
• Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in ChinaRecruitingNCT07161388
• DESTINY-PANTUMOUR04RecruitingNCT07124000
• Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung CancerCompletedNCT04774380Phase 3Results posted
• Study of AZD2811 + Durvalumab in ES-SCLCActive, not recruitingNCT04745689Phase 2Results posted
• Durvalumab Plus Chemotherapy in Untreated Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04712903Phase 3Results posted
• Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)CompletedNCT04449861Phase 3Results posted
• Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation TherapyActive, not recruitingNCT03703297Phase 3Results posted
• Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)Active, not recruitingNCT03043872Phase 3Results posted
• A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung CancerCompletedNCT02937818Phase 2Results posted
• A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.Active, not recruitingNCT02734004Phase 1/2Results posted
• Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.Active, not recruitingNCT06992609Phase 3
• REAL-WORLD DURVALUMAB IN EXTENSIVE-STAGE SMALL CELL LUNG CANCERCompletedNCT06826677
• A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in BrazilActive, not recruitingNCT06008353
• A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.Active, not recruitingNCT05683977
• A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung CancerTerminatedNCT04870112Phase 1
• Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:CompletedNCT04836975
• First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid TumoursCompletedNCT04504669Phase 1
• A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid TumorsCompletedNCT03811652Phase 1
• Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid TumorsCompletedNCT03509012Phase 1
• Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid TumorsCompletedNCT02658214Phase 1
• A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.CompletedNCT02579226Phase 1
• AZD1775 Combined With Olaparib in Patients With Refractory Solid TumorsCompletedNCT02511795Phase 1
• Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid TumoursCompletedNCT02482311Phase 1
• A Study of IRESSA in Relapsed and Refractory Small Cell Lung CancerCompletedNCT00298688Phase 2